Browsing Category
Pharma Industry News
4747 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can AI trial matching close the gap in cancer drug access?
Can AI fix clinical trial access in cancer care? Discover how Tempus, TrialJectory, and CureMatch are using intelligent platforms to democratize treatment pathways.
Myopia drug breakthrough: Sydnexis’ SYD-101 approved in Europe, Ryjunea launch next
Sydnexis, Inc., a privately held U.S. biopharmaceutical company, secured a critical regulatory victory on June 5, 2025, with…
Cell therapy in solid tumors: Breakthroughs, delivery challenges, and what’s next
Discover how new trials and biotech innovations are tackling the biggest hurdles in adapting cell therapy for solid tumors. See what’s changing now.
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
Ajinomoto strengthens U.S. pharma operations with $2.1m lab upgrade in Raleigh
Ajinomoto Health & Nutrition (TYO: 2802) opens a $2.1M QC lab in Raleigh, strengthening global API leadership. Pharma-grade amino acid growth in focus.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.
Agenus–Zydus $141m immuno-oncology deal sets stage for global BOT/BAL expansion and U.S. biologics manufacturing pivot
Agenus partners with Zydus in a $141M deal to expand BOT/BAL globally and transfer U.S. biologics assets—find out what it means for cancer immunotherapy.
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
Leyden Labs secures €20m from European Investment Bank: Could this reshape Europe’s pandemic response strategy?
Leyden Labs secures €20M EIB funding under HERA Invest to develop intranasal antibody sprays targeting pandemic flu and respiratory threats.